International Journal of Breast Cancer最新文献

{"title":"T-Cell Immunoglobulin and Mucin Domain 1 (Tim1) as a Prognostic Factor Associated With Therapeutic Resistance in Human Breast Carcinoma.","authors":"Mio Yamaguchi-Tanaka, Kiyoshi Takagi, Mai Sawafuji, Ai Sato, Kanoko Nakamura, Yasuhiro Miki, Minoru Miyashita, Takashi Suzuki","doi":"10.1155/ijbc/3747828","DOIUrl":"10.1155/ijbc/3747828","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic resistance, including resistance to endocrine therapy in ER-positive tumors and to chemotherapy in aggressive subtypes, remains a major clinical challenge in breast cancer. T-cell immunoglobulin and mucin domain 1 (Tim1), a Type I transmembrane glycoprotein, has been reported to be aberrantly expressed in various cancer cells and contribute to tumor progression. However, its clinical significance in breast cancer and association with therapy resistance remain largely unclear.</p><p><strong>Methods: </strong>We investigated Tim1 expression by immunohistochemistry in 116 breast carcinoma tissues and analyzed its correlation with clinicopathological parameters and clinical outcomes according to chemotherapy and endocrine therapy status.</p><p><strong>Results: </strong>Tim1 immunoreactivity was detected in the cytoplasm and cell membranes of breast carcinoma cells but was negligible in the normal breast epithelium. Tim1 expression was significantly associated with pathological T factor, lymph node metastasis, histological grade, and Ki67 labeling index. Tim1 immunoreactivity was significantly correlated with an increased risk of recurrence, and multivariate analyses demonstrated Tim1 as an independent adverse prognostic factor for disease-free survival. In addition, Tim1 remained correlated with the risk of recurrence in patients who had received chemotherapy or endocrine therapy.</p><p><strong>Conclusions: </strong>Tim1 might be an important therapeutic target for improving therapy in breast cancer patients and could be a strong adverse prognostic factor associated with therapeutic resistance.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"3747828"},"PeriodicalIF":1.9,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13081791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147700084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of Dosimetry Planning in 3D Conformal Radiotherapy for Breast Cancer With Lymph Nodes Using the High-Tangential Tilted-Supraclavicular Technique.","authors":"Mazen Moussallem","doi":"10.1155/ijbc/2650553","DOIUrl":"10.1155/ijbc/2650553","url":null,"abstract":"<p><strong>Purpose: </strong>Despite the emergence of advanced radiotherapy techniques such as volumetric modulated arc therapy (VMAT), three-dimensional conformal radiotherapy (3DCRT) continues to be used due to its advantages in treating breast cancer. This study aimed to optimize the 3DCRT technique for breast cancer cases that require lymph node irradiation.</p><p><strong>Methods and materials: </strong>A total of 100 consecutive patients were included. For the first 50 patients, standard (ST) 3DCRT dosimetry plans were prepared. For the remaining 50 patients, plans were generated using an optimized High-tangential Tilted-supraclavicular (HT) technique, which consists of tilting the supraclavicular beam to reduce ipsilateral lung irradiation; raising the tangential fields superiorly to enhance coverage of axillary levels I and II; and intentionally creating an internal overlap between the supraclavicular and tangential fields. This overlap was resolved using the field-in-field (FIF) technique, primarily applied to the supraclavicular field, which is the main contributor to ipsilateral lung dose in this region.</p><p><strong>Results: </strong>The HT technique demonstrated promising results compared with the ST technique and other published 3DCRT methods. It achieved improved coverage of axillary levels I and II while reducing the dose to the ipsilateral lung. However, further adjustments are needed to enhance coverage of axillary level III, the supraclavicular region, and internal mammary nodes (IMN). These include the following: completing targets contouring prior to dosimetry planning to enable precise field adjustments; relaxing the 2 cm constraint on ipsilateral lung irradiation by tangential fields when IMN is included; relaxing the maximum dose constraint for the supraclavicular and IMN fields; and using a fully electron-based field instead of a mixed electron-photon technique for IMN dedicated field.</p><p><strong>Conclusions: </strong>The HT technique was quantitatively validated, and a modified version was proposed and qualitatively assessed. This new version may be considered for clinical use, and comparison with VMAT in a larger patient cohort is recommended.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"2650553"},"PeriodicalIF":1.9,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13081798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147700045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MMTV Virus Detection, Survival Analysis, and Prognostic Relevance of Six Tumor Genes in Patients With Breast Cancer.","authors":"Saad Alamri, Maaweya Awadalla, Rahaf A Henawi, Ghaida Al-Hazzaa, Zahra Alkhunaizy, Soha Alzorgi, Nouf Alqahtani, Alyaa S Abdel Halim, Mohamed A M Ali, Mansour I Almansour, Bandar Alosaimi","doi":"10.1155/ijbc/3310843","DOIUrl":"10.1155/ijbc/3310843","url":null,"abstract":"<p><strong>Background/objectives: </strong>Breast cancer (BC) remains the most frequently diagnosed malignancy among women worldwide and represents a significant global health burden. The genes associated with tumor suppression (p53, BRCA1, and BRCA2), telomere length maintenance (TERT), DNA damage response (FGFR2), and DNA repair (CHD1) are recognized for their intricate function in tumor genesis and progression. However, the prognostic significance of these genes in BC remains an area of research interest. This study aimed to examine the potential association between the presence of the MMTV and the expression patterns of these six genes with patient prognosis and survival outcomes in BC.</p><p><strong>Methods: </strong>This study includes 125 formalin-fixed, paraffin-embedded (FFPE) tissue specimens taken from BC patients, in addition to 25 tissue samples of benign breast lesions were incorporated as controls. The mRNA expression levels of six genes, namely p53, BRCA1, BRCA2, TERT, FGFR2, and CHD1, were quantified in FFPE tissue samples using quantitative polymerase chain reaction (qPCR). The correlation between gene expression and prognostic characteristics and the probability of recurrence-free survival (RFS) and overall survival (OS) were assessed.</p><p><strong>Results: </strong>The results do not indicate an association between MMTV and BC, as the virus was not detected in any of the tissue samples analyzed. We observed a significant differential expression in five of the six studied genes between BC and noncancerous breast tissue, with significant downregulation of BRCA1, BRCA2, CHD1, and TERT, significant upregulation of p53, and unchanged levels of FGFR2. Among BC patients, p53 and BRCA1 expression levels emerged as significant prognostic factors for both RFS (32 vs. 24 months; 34 vs. 26 months) and OS (28.5 vs. 24 months; 31 vs. 28 months), respectively. Kaplan-Meier survival analysis of p53 expression displayed a trend favoring low expression for better survival and showing relatively stable RFS and OS survival curves of p53 until 43 and 54 months of the follow-up period, respectively.</p><p><strong>Conclusions: </strong>When comparing cancer to noncancer patients, only p53 and BRCA1 expression levels emerged as significant prognostic factors for both RFS and OS in the entire cohort, with p53 displaying a trend favoring low expression for better survival. Although gene expression data provided a prognostic value, future studies should aim at integrating multiomics data and evaluating biomarkers in a broader clinical context to improve the accuracy of prognostic models and guide personalized treatment strategies.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"3310843"},"PeriodicalIF":1.9,"publicationDate":"2026-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13071179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147692783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Rural Breast Cancer Screening Uptake: A Three-Arm Comparative Study of Outreach Strategies.","authors":"Komal Verma Saluja, Sangeeta Saxena, Mohammed Shadab Gouri, Priyanka Sangar, Sakshi Sharma, Harshvardhan Khokhar, Reshma Reja","doi":"10.1155/ijbc/4070359","DOIUrl":"10.1155/ijbc/4070359","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most prevalent cancer among women, with a notably high mortality-to-incidence ratio, especially in rural areas. Limited awareness and inadequate access to healthcare are major contributors to the high breast cancer mortality rate in rural women, often resulting from insufficient screening, delayed diagnosis, and treatment.</p><p><strong>Objectives: </strong>This study is aimed at evaluating the effectiveness of three distinct intervention strategies-medical personnel-led education, breast health volunteers, and mobile screening mammography van visits-in improving breast cancer awareness, increasing screening participation, and reducing associated stigmatization among rural women.</p><p><strong>Methods: </strong>A comparative, community-based interventional study was conducted in three villages in neighboring districts. Rural communities were randomly allocated to one of the three intervention strategies. Baseline and postintervention data were collected using validated structured questionnaires assessing breast cancer knowledge, screening practices, stigma, and perceived barriers.</p><p><strong>Results: </strong>A total of 944 women aged 30-70 years were enrolled in the study. Overall, 63.7% of participants underwent screening. The mobile screening mammography van group achieved the highest screening uptake (68.7%) and the greatest increase in awareness scores, whereas the breast health volunteer-led group showed the most significant reduction in stigma. The medical personnel-led group, though cost-effective in raising awareness, recorded lower screening participation and reported higher perceived barriers to screening mammography (e.g., transport, time, and financial constraints).</p><p><strong>Conclusion: </strong>The findings demonstrate that integrated, culturally tailored interventions, particularly those combining community engagement with accessible on-site screening services, can effectively improve breast cancer awareness and screening uptake among rural women. Scaling up such multicomponent strategies may help overcome logistical and sociocultural barriers, ultimately contributing to earlier detection and reduced mortality.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"4070359"},"PeriodicalIF":1.9,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13069145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modifiable and Nonmodifiable Risk Factors for Breast Cancer: A Comprehensive Scoping Review.","authors":"Zohre Momenimovahed, Zahra Shahabinia, Leila Allahqoli, Hamid Salehiniya","doi":"10.1155/ijbc/8689986","DOIUrl":"10.1155/ijbc/8689986","url":null,"abstract":"<p><strong>Background and objectives: </strong>This scoping review focuses on gathering and examining the literature regarding modifiable and nonmodifiable risk factors for breast cancer.</p><p><strong>Materials and methods: </strong>A comprehensive search was conducted in the PubMed/MEDLINE, Scopus, and Web of Science Core Collection databases with the keywords \"breast cancer\", \"risk\", and \"risk factor\" and a combination of these words to find quality articles published from 2010 to January 2025.</p><p><strong>Results: </strong>In total, 169 articles published in English were included in the study. The findings of this study revealed that family history, genetics, blood group, race, previous history of breast cancer, sex hormones, and breast density are nonmodifiable risk factors for this cancer. Smoking, alcohol, coffee and tea consumption, a low level of physical activity, dietary regimens, hormone replacement therapy, contraceptive pills, reproductive factors, no breastfeeding, metabolic syndrome, obesity, diabetes, some medications, work status, and other diseases are modifiable risk factors that play a role in the occurrence of breast cancer.</p><p><strong>Discussion: </strong>Lifestyle modifications such as improving one's diet, engaging in regular physical activity, avoiding smoking/passive smoking, limiting alcohol consumption, maintaining a healthy weight after menopause, optimizing long-term nonhormonal fertility choices, avoiding medically unnecessary hormone increases, and performing genetic screening when necessary can help in the prevention of breast cancer.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"8689986"},"PeriodicalIF":1.9,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13058239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147647016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thymoquinone Enhances Tamoxifen Efficacy Against Triple-Negative Breast Cancer by Targeting EMT Signaling.","authors":"Mazharul Haque, Ritis K Shyanti, Sudhanshu Sharma, Hongzhuan Wu, Manoj K Mishra","doi":"10.1155/ijbc/1780945","DOIUrl":"10.1155/ijbc/1780945","url":null,"abstract":"<p><p>The variety of available therapies for treating TNBC is constrained by the minimal or no expression of receptors such as estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2). However, estrogen receptor <i>β</i> (ER<i>β</i>) has emerged as a potential therapeutic target for TNBCs. Tamoxifen (TAM) is used as an endocrine therapy against ER-positive cancer but has minimal impact on ER-negative cancers like TNBC. Thymoquinone (TQ) is an active natural compound with anticancer properties, as evidenced by a cumulative number of reports. A combinatorial approach to targeting EMT in TNBC is one strategy that may improve TAM activity. In this study, we evaluated the binding affinity and stability of TQ and TAM with ER<i>β</i> in silico and assessed their cytotoxic potential individually and in combination in vitro. Docking and molecular dynamics (MD) studies confirmed interactions between ER<i>β</i> and TQ, TAM, and GEN. The IC₅₀ values for TQ and TAM were approximately 18.44 and 11.76 <i>μ</i>M, respectively, for MDA-MB-468, and 22.06 and 15.73 <i>μ</i>M, respectively, for MDA-MB-231. An in vitro study demonstrated enhanced cytotoxic effects when TQ (20 <i>μ</i>M) and TAM (13 <i>μ</i>M) were combined. Further analysis revealed downregulation of the mesenchymal markers CDH2 (N-cadherin) and vinculin, which are responsible for cell migration. Additionally, low vimentin and enhanced E-cadherin expression lead to downregulation of core EMT regulators, including SNAIL1 and ZEB1. In conclusion, TQ showed potential chemomodulatory effects on TAM against TNBC by reducing the expression of EMT-associated markers.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"1780945"},"PeriodicalIF":1.9,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13053650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Adjuvant Chemotherapy on Survival Outcomes in Intermediate- and High-Risk ER+/HER2- Breast Cancer Stratified by Genomic Profiling: A Meta-Analysis.","authors":"Max Seabrook, Ahamed S M Navas, Hannah-Maria Francis, Zina Aladili, Ahsan Rao","doi":"10.1155/ijbc/4973135","DOIUrl":"10.1155/ijbc/4973135","url":null,"abstract":"<p><strong>Background: </strong>Genomic recurrence score (RS) testing guides adjuvant treatment decisions in oestrogen receptor-positive, HER2-negative early breast cancer. Evidence remains mixed regarding the survival benefit of adding chemotherapy to endocrine therapy (CET) in intermediate- and high-risk RS groups. This meta-analysis assessed overall mortality, breast cancer-specific mortality (BCSM) and recurrence outcomes according to RS category.</p><p><strong>Methods: </strong>Medline, Embase, PubMed and Google Scholar were searched from 1 January to 20 June 2024 for studies reporting outcomes in ER+/HER2- patients treated with CET versus endocrine therapy (ET) alone, stratified by RS. Random-effects modelling generated pooled risk ratios (RRs) with 95% confidence intervals (CIs). Heterogeneity was evaluated using <i>I</i> ², and risk of bias was assessed with ROBINS-I.</p><p><strong>Results: </strong>Fifteen studies comprising 630,741 patients were included. In the high-risk group (RS > 25), CET significantly reduced 5-year overall mortality compared with ET (5.9% vs. 7.9%; RR 0.57, 95% CI 0.45-0.72; <i>I</i> ² = 91<i>%</i>). Node-negative high-risk patients also showed improved survival (RR 0.48, 95% CI 0.37-0.64; <i>I</i> ² = 77<i>%</i>). BCSM was lower with CET in high-risk patients (RR 0.81, 95% CI 0.67-0.97; <i>I</i> ² = 0<i>%</i>). In the intermediate-risk group (RS 11-25), CET did not significantly reduce overall mortality (RR 0.72, 95% CI 0.49-1.06; <i>I</i> ² = 94<i>%</i>) or BCSM (RR 1.28, 95% CI 0.91-1.79; <i>I</i> ² = 45<i>%</i>). Subgroup analysis of RS 16-25 showed lower overall mortality with CET (RR 0.48, 95% CI 0.42-0.55; <i>I</i> ² = 0<i>%</i>), although BCSM was similar. Data for 5-year recurrence outcomes were insufficient for pooled analysis.</p><p><strong>Conclusion: </strong>Chemotherapy provides a clear survival benefit in high-risk RS groups, including node-negative patients, whereas intermediate-risk groups show limited benefit. These findings support selective use of CET guided by genomic risk stratification.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"4973135"},"PeriodicalIF":1.9,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13053945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Chewing Tobacco and the Risk of Breast Cancer in Indian Women: A Multicentre Case-Control Study.","authors":"Romi Moirangthem, Ankita Manjrekar, Gayathri B Pullat, Shruti Vishwas Golapkar, Ruchita Sahdev Margale, Sakshi Sagare, Dipakshi Talukdar, Nandini Chakraborty, Ruchi Pathak, Satyajit Pradhan, Manigreeva Krishnatreya, Nandkumar Panse, Rajesh Dikshit, Isabelle Soerjomataram, Sudeep Gupta, Sharayu Mhatre","doi":"10.1155/ijbc/2950851","DOIUrl":"10.1155/ijbc/2950851","url":null,"abstract":"<p><strong>Background: </strong>Even though breast cancer (BC) is the most common female cancer worldwide, the role of tobacco, specifically chewing tobacco in the development of BC has not been widely studied. This study is aimed at assessing this association.</p><p><strong>Methods: </strong>A multicentre hospital-based case-control study was utilised. Two thousand five hundred fifty-three histopathologically confirmed BC cases, and 2239 visitor controls were included. Self-reported information was collected regarding tobacco consumption and other potential confounders. A logistic regression model was used to calculate odds ratio (OR) and its 95% confidence interval (CI), after adjusting for age, current residential region, education, various reproductive factors, BMI and history of benign breast lump. Attributable fraction (AF) and population attributable fraction (PAF) of BC due to chewing tobacco were also calculated.</p><p><strong>Results: </strong>An increased risk of BC was observed in women who ever used chewing tobacco (OR:1.19, 95% CI:1.00-1.41) as compared to those who never consumed tobacco (smoking and chewing), consistent across all subtypes of BC. A dose-response relation was observed for duration of tobacco chewing (OR_{>25 years}: 1.38, 95% CI: 1.04-1.83). Women who initiated chewing tobacco at < 20 years, before their first full-term pregnancy (FFTP), had more risk. Observed association was consistent even after stratification on menopausal status. The AF of BC due to tobacco chewing in our study was calculated to be approximately 3%, whereas the PAF for India was about 2%.</p><p><strong>Conclusion: </strong>Our study suggests that chewing tobacco is associated with an increased risk of BC for all subtypes. This is particularly true when the duration of exposure is higher and exposure begins before FFTP. This highlights the need to target tobacco control policies to smokeless tobacco along with smoking, thus reducing the burden of BC to some extent.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"2950851"},"PeriodicalIF":1.9,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12969211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Serum Vitamin B12 Levels as a Potential Biomarker for Solid Tumors in Jordanian Patients: A Retrospective Case-Control Study.","authors":"Sahar Kamal Otoom, Lobna Gharaibeh, Anas Abed, Ibrahim Aldeeb","doi":"10.1155/ijbc/7833513","DOIUrl":"10.1155/ijbc/7833513","url":null,"abstract":"<p><strong>Background: </strong>Vitamin B12 deficiency is classically associated with anemia and neurological dysfunction. However, recent studies suggest that elevated plasma vitamin B12 may indicate increased short-term cancer risk. This association remains largely unexplored in Middle Eastern populations, including Jordan, where cancer rates are rising and diagnosis often occurs at advanced stages due to limited screening.</p><p><strong>Objective: </strong>This study is aimed at investigating the association between serum vitamin B12 levels and the risk of colorectal, breast, and lung cancers in a Jordanian population, evaluating differences by cancer type and stage.</p><p><strong>Methods: </strong>A retrospective case-control study was conducted at King Abdullah University Hospital, Jordan, from January 2018 to December 2022. The study enrolled 260 patients diagnosed with colorectal, breast, or lung cancer and 260 matched healthy controls. Data collected included sociodemographic factors, clinical characteristics, and serum vitamin B12 levels.</p><p><strong>Results: </strong>Serum vitamin B12 levels were significantly higher in cancer patients compared with controls (579.23 ± 468.72 vs. 492.70 ± 174.36 pg/mL; <i>p</i> = 0.005). High vitamin B12 levels (> 800 pg/mL) occurred in 15.8% of cancer patients versus 1.5% of controls (<i>p</i> < 0.001). Vitamin B12 levels varied significantly by cancer type, being highest in lung cancer patients (669.53 ± 566.59 pg/mL) compared with breast (594.86 ± 468.9 pg/mL) and colorectal cancer patients (439.62 ± 291.89 pg/mL; <i>p</i> = 0.024). There was a strong positive correlation between vitamin B12 levels and cancer stage, peaking in Stage IV cancers, <i>r</i> = 0.629, <i>p</i> = 0.001.</p><p><strong>Conclusion: </strong>Elevated serum vitamin B12 levels are significantly associated with solid cancers in Jordanian patients, particularly pronounced in lung cancer and advanced stages. These findings do not imply a causal relationship, but rather suggest that serum vitamin B12 may function as a potential biomarker for cancer detection and disease monitoring in resource-limited settings.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"7833513"},"PeriodicalIF":1.9,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12964162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Influencing Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Retrospective Study Focusing on ER and HER-2 Status.","authors":"Yadong Zhang, Shubian Qiu, Xin Wang","doi":"10.1155/ijbc/6694023","DOIUrl":"10.1155/ijbc/6694023","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To identify predictive factors of pathological complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC), and to establish a \"clinical-imaging-molecular\" three-dimensional evaluation model to guide clinical decision-making.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective study was conducted on 55 breast cancer patients who underwent NAC at Nanyang Second People's Hospital from January 2023 to August 2024. Collected data included demographic variables (age, BMI, and menstrual status), tumor characteristics (tumor size, axillary lymph node [N] stage, histological grade, color Doppler ultrasound features including blood flow signal [CDFI], morphology, and aspect ratio), molecular markers (estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor-2 [HER-2], and Ki-67), and treatment-related factors (chemotherapy regimen). Univariate analyses (Pearson's chi-square test or Fisher's exact test) were initially conducted to screen variables potentially associated with pCR (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). To address potential multicollinearity among clinically relevant factors, binomial LASSO regression with 10-fold cross-validation was applied to select parsimonious predictors (variables with nonzero coefficients were retained), which were then incorporated into multivariate logistic regression to determine independent predictors of pCR. The discriminative power of key factors was evaluated using receiver operating characteristic (ROC) curves, with the area under the curve (AUC) as the primary metric.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The overall pCR rate was 36.4% (20/55). Among molecular subtypes, HER-2-positive patients (40.0% of the cohort) had the highest pCR rate (73.0%, 16/22), followed by triple-negative breast cancer (TNBC) patients (15.0% of the cohort, 50.0%, 4/8). Univariate analysis showed that N stage, chemotherapy regimen, Ki-67 index, ER status, PR status, and HER-2 status were significantly correlated with pCR (all &lt;i&gt;p&lt;/i&gt; &lt; 0.05). ROC analysis demonstrated excellent discriminative performance for ER (AUC = 0.84), HER-2 (AUC = 0.81), PR (AUC = 0.79), chemotherapy regimen (AUC = 0.71), and Ki-67 (AUC = 0.68). After LASSO-based dimension reduction, multivariate logistic regression confirmed that ER negativity (&lt;i&gt;p&lt;/i&gt; = 0.039, OR = 15.079, 95% CI: 1.151-197.543) and HER-2 positivity (&lt;i&gt;p&lt;/i&gt; = 0.044, OR = 0.014, 95% CI: 0.000-0.896) were independent predictors of higher pCR rates.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;pCR rates in breast cancer patients post-NAC vary significantly by molecular subtype. ER negativity and HER-2 positivity emerge as independent predictive factors for pCR, with ER and HER-2 exhibiting the strongest discriminative ability (AUC &gt; 0.8). Clinicians should integrate patients' baseline clinical data, ultrasound features, and molecular markers to screen optimal NAC candidates and develop individualized strategies, thereby maximizing thera","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"6694023"},"PeriodicalIF":1.9,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12956846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147366972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}